Background: Children with nonsyndromic orofacial clefts (NS OFCs) may require exceptional children's (EC) services for academic delays. We examined EC service use of children with and without NS OFCs in NC in elementary school.
Methods: We included 559 children with NS OFCs and 6,822 children without birth defects who had NC educational records. We estimated prevalence ratios, trends in enrollment, and characteristics of eligibility classification using descriptive statistics and logistic regression by cleft subtype and race/ethnicity. We estimated the odds of third grade retention by EC enrollment using logistic regression with inverse probability of treatment weights.
Results: Children with NS OFCs were 3.02 (95% CI: 2.50, 3.64) times as likely to receive third grade special education (SE) services compared to unaffected peers. The prevalence odds was highest among children with CL+P (OR: 4.61, 95% CI: 3.49, 6.09) declining by 54% by fifth grade. The prevalence odds of SE for white children was approximately 1.50 times that for African American children in fourth and fifth grades. Approximately 33% of children with NS OFCs within each racial/ethnic group received SE in third grade. African American children were twice as likely to receive services under specific learning disability. Children with NS OFCs receiving EC services were 44% (OR: 0.56; 95% CI: 0.13, 2.38) less likely to be retained in third grade compared to children with NS OFCs who were not receiving services.
Conclusions: Children with NS OFCs are more likely to receive SE services in elementary school compared to their unaffected peers. The eligibility category differed by racial/ethnic group.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/bdr2.1418 | DOI Listing |
J Allergy Clin Immunol Pract
January 2025
University of Queensland, St Lucia, Australia; Centre for Food Allergy Research, Murdoch Children's Research Institute, Parkville, Australia. Electronic address:
Background: Following a negative oral food challenge (OFC), it is recommended the individual continues to consume the historical allergen regularly. However, the proportion of families achieving sustained reintroduction, and enablers and barriers for reintroduction, are currently unclear.
Objective: To understand the frequency and definitions of optimal food reintroduction in children and adolescents following negative OFC, and associated barriers and enablers.
JCI Insight
January 2025
Division of Pediatric Allergy, Immunology, and Rheumatology, Department of Pediatrics, John Hopkins University School of Medicine, Baltimore, Maryland, USA.
BACKGROUNDCow's milk (CM) allergy is the most common food allergy in young children. Treatment with oral immunotherapy (OIT) has shown efficacy, but high rates of adverse reactions. The aim of this study was to determine whether baked milk OIT (BMOIT) could reduce adverse reactions while still inducing desensitization, and to identify immunological correlates of successful BMOIT.
View Article and Find Full Text PDFAllergol Int
December 2024
Department of Allergy, Clinical Research Center for Allergy and Rheumatology, NHO Sagamihara National Hospital, Kanagawa, Japan. Electronic address:
Background: Low-dose (LD) oral food challenge (OFC) with heated cow's milk (CM; 3 mL) effectively prevents CM elimination in children with CM allergy (CMA). We investigated the long-term prognoses after an LD-OFC for CMA.
Methods: Children with immediate CMA symptoms after consuming <25 mL of CM within 2 years of a baseline LD-OFC were retrospectively analyzed.
Eur Child Adolesc Psychiatry
December 2024
Department of Plastic Surgery, Evelina Hospital, St Thomas' Hospital, London, UK.
Individuals with orofacial clefts (OFCs) may be at an increased risk of developing autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD). This systematic review provides a summary of the most recent data regarding the prevalence of ASD and ADHD in the OFC population and compares this to the general paediatric population. Multiple databases were searched including PubMed/Medline and Embase in July 2024, following the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines and was registered in PROSPERO (CRD42024565219).
View Article and Find Full Text PDFArerugi
December 2024
Department of Allergy, Clinical Research Center for Allergy and Rheumatology, NHO Sagamihara National Hospital.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!